Hepatoxicity Screening Webinar On Demand


The ability to predict the pharmacokinetic and toxicological properties of a drug early in the development process can materially reduce the likelihood of clinical failure, and subsequently the total cost of development. As such, there is a substantial and accelerating drive to identify model systems that more accurately predict human physiological responses to xenobiotics.

To fill the obvious gap in the drug development process, Visikol presents the HUREL Micro Liver model system. HUREL Micro Livers consist of cryopreserved primary hepatocytes co-cultured with a stromal fibroblast cell line, which aids in the hepatocytes’ maintenance of more in vivo-like characteristics compared to traditional hepatic mono-cultures, including long term viability and retention of cytochrome P450 isozyme activity. Combining the HUREL Micro Liver model system with Agilent’s impedance-based, label-free, xCELLigence real-time cell analysis (RTCA) technology allows for continuous monitoring of toxicity and ensures that no meaningful time points are missed.

In this webinar, Dr. Amir Wahba, senior principal scientist at Visikol Inc. will illustrate how real-time data enables identification of optimal treatment times and data collection, in addition to the evaluation of cytotoxicity onset and kinetics.

Webinar topics include:

  • The challenge of drug-induced hepatoxicity
  • Development of predictive in vitro model systems
  • The combination of Visikol’s HUREL and Agilent’s xCELLigence Technology

For Research Use Only. Not for use in diagnostic procedures. 


Amir Wahba, PhDAmir Wahba, PhD
Senior Principal Scientist
Visikol Inc.

Dr. Amir Wahba is a senior principal scientist at Visikol Inc. In his current role, he leads the bioanalytical assay development in collaboration with the in vitro and the pharmacology teams utilizing LC-MS/MS. Dr. Wahba holds a Ph.D. in Pharmacognosy from the University of Mississippi, emphasizing the chemistry of natural products. During his graduate work, Dr. Wahba focused on discovering and developing anti-cancer and anti-malarial drug leads from the marine environment. He pioneered the structure elucidation of bioactive natural products and the development of in vitro platforms for the active compound’s evaluation. Following his postdoctoral training on carbohydrate synthesis at LSU, Dr. Wahba expanded his drug discovery skills to include nanotechnology, molecular biology, gene therapy, and metabolomic analysis by contributing to multidisciplinary projects in academia and industry. Before joining Visikol, Dr. Wahba served as a senior research associate at the Department of Neurosurgery at Robert Wood Johnson Medical School, Rutgers University, where he established an adenosine-based epigenetic drug discovery platform based on manipulating adenosine metabolism through small molecules and gene-based intervention for epilepsy and brain cancer treatment. Furthermore, he established the protein-protein interaction network of adenosine kinase utilizing mass spectrometry proteomics and metabolomics approaches to help us understand the consequence of adenosine kinase manipulation on cancer metabolism.

2023-02-02T08:34:46-05:00Tags: , , |

Share This Page, Choose Your Platform!